Shares of Moderna surged 10.8% to $170.63 Monday after the company announced its personalized mRNA melanoma vaccine data secured a coveted Presidential Symposium slot at the European Society for Medical Oncology (ESMO) Congress in Madrid this October. ESMO reserves Presidential Symposium presentations for "cutting-edge and significant clinical practice-changing studies." No new efficacy figures accompanied the announcement — the market is essentially betting that the data, when revealed October 24, will be strong enough to reshape how doctors treat melanoma after surgery.

  • A Conference Invitation Is Doing the Heavy Lifting. Moderna said three abstracts were accepted for ESMO 2026 in Madrid, with the flagship Phase 3 melanoma data assigned the LBA1 slot in the Presidential Symposium on October 24. That designation signals ESMO's own reviewers consider the results potentially practice-changing. But investors still haven't seen key numbers: no effect size was released when the Phase 3 success was first announced in August. Today's rally is a bet on the packaging, not the contents.

  • The August Moonshot Already Priced In Enormous Expectations. Moderna's stock soared about 177% on the day the Phase 3 success was announced, adding roughly $45 billion in market value. William Blair projected Moderna could earn $5.4 billion in peak annual melanoma sales from its 50-50 split with Merck, though Evercore ISI cautioned the new valuation "already prices in substantially more conviction than the data disclosed thus far supports." Today's move adds another ~$7 billion, pushing the stock within striking distance of its 52-week high of $176.66.

  • The Revenue Picture Is Still Years Away — And the Losses Are Real. Moderna's latest quarter showed revenue of just $145 million, up only 2.1% year-over-year, and the consensus estimate for the September quarter is a loss of $1.36 per share.

GlobalData projects intismeran sales surpassing $1 billion by 2031, but the vaccine isn't approved anywhere yet and analysts flag high per-patient manufacturing costs and uncertain expansion to other cancers.

  • The Real Reveal Comes October 24. The Phase 2 follow-up showed a 49% reduction in recurrence or death risk versus Keytruda alone. If Phase 3 hazard ratios match or exceed that bar, approval filings could follow swiftly. Moderna and Merck are already testing the vaccine in bladder, kidney, pancreatic, and stomach cancers, meaning strong melanoma data would validate the entire platform. A disappointment, however, would unwind a stock that carries a consensus analyst target of just $76.72 — less than half today's price.